Alzamend Neuro Ends BD Trial SOW, Seeks FDA Guidance on AL001 Development
Alzamend Neuro terminated its bipolar disorder trial and related statement of work, receiving a $25,000 refund. The FDA advised against broader eligibility criteria, suggesting efficacy and safety trials for an NDA. The company plans to request FDA guidance for a revised plan, including a Phase III trial, and expects to announce trial results in December 2026 and FDA feedback by Q2 2027, according to an SEC filing.
How this was made

The 30-second read
Why it matters
FDA did not support broader eligibility criteria and indicated efficacy and safety trials may be more appropriate to support an NDA, prompting a trial pause and SOW termination. Management plans a Type B meeting and expects to move directly to a Phase III BD trial, while also targeting December 2026 final healthy-subject results and FDA feedback by end of Q2 2027.
Market read
This is a development-path disruption for ALZN, with FDA guidance and a paused trial that can materially affect perceived probability of success and timing to NDA.
What to watch
The article also notes a completed healthy-subject trial with final results expected in December 2026, which could partially offset timeline concerns if data are strong.
Background
Alzamend Neuro is developing AL001 for bipolar disorder; the company is revising its development plan after FDA feedback.
Ticker impact
Alzamend Neuro’s bipolar disorder BD trial was paused and its BD statement of work terminated as it seeks FDA guidance on a revised AL001 plan.
Likely downside pressure as investors price in slower timelines and higher probability of additional trial work before an NDA.
The article cites a paused trial, terminated SOW, and FDA non-support for the proposed eligibility approach, plus a shift toward a Phase III plan after a Type B meeting.
Market effects
Highlights FDA scrutiny on trial design and eligibility criteria for CNS indications, which can weigh on sentiment for similar pre-NDA biotech programs.
No clear regional market linkage beyond US biotech risk appetite.
Limited, as the catalyst is company-specific FDA guidance and trial management.
Counterpoint
The pause and SOW termination could be viewed as a corrective step that improves the odds of an eventual NDA by aligning the program with FDA expectations.
Key entities
- companyAlzamend Neuro, Inc.
Subject of the SEC filing; paused its BD trial and is seeking FDA guidance on a revised AL001 development plan.
- drug_programAL001
Bipolar disorder candidate whose development plan is being revised following FDA feedback.
- regulatorFDA
Provided guidance rejecting broader eligibility criteria and suggesting efficacy and safety trials for NDA support.
- research_partnerMGH
Terminated the BD statement of work after the trial was paused and will provide an approximately $25,000 refund.